1D·

+++ What's going on with Hims +++

I often read FOMO in both directions here at $HIMS (+1.86%)


Many are now starting to invest or are partially liquidating their positions, and there are more and more traders who are trying to trade the range of $30 - $70 USD, as this has been successful four times this year.


Why did Hims fall?


Roughly: The elimination of GLP-1 as a direct deal with $NOVO B (+0.58%) has led to them selling again in a gray area and a lawsuit is always on the table. In addition, compounders have lowered their prices, which has minimized the gap to H&H somewhat. This has meant that Hims has less growth in the GLP-1 area and therefore growth of ~40% is expected for Q3

attachment

In addition, ARPU has declined somewhat and Hims has lost momentum in subscriber growth. However, I only see this as a short-term problem as I have adjusted the GLP-1 business and see it as a cash position. In addition, the management is sticking to the 2030 targets which would lead to a FWD P/S of 1.4!!!

attachment

The sell-off was also initiated by the sale of shares by the CEO / by the management restructuring and by current market momentum. These factors have led to the current share price decline.


My position has halved since February due to the current price drop, but I am currently considering small purchases (I am an unliquid student) to increase my position a little.


This as a small suggestion, we currently have a P/S of ~3.3!!! I'm off to university now. More to follow

14
8 Comments

profile image
What does P/S of 3.3 mean? Don't just write that and go to university. Is that good? Is it bad? Comparative values?
2
profile image
@Joris Ratio of share price to sales
profile image
@Joris It is often not so easy to determine meaningful comparative values!

As a rule, the industry average is used here. Alternatively, the average of the competition. However, this is difficult because competitors are often in different locations. Especially with pharma:
- Research start-ups
- growth company
- Profitable growth company
- high/small margins

As you can see, there are many ways to determine this!

Theoretically, you can take the multiple of a generics manufacturer. But here again: not quite the same. Hims has an attractive brand and its own platform. As a result, you can expect significantly higher margins in the long term (once the company has grown).
profile image
Slowing growth and increased debt are going in the wrong direction.
1
@Olli68 It doesn't matter what the reality is, the $HIMS disciples talk themselves up 😂
1
profile image
@Pacco93 I'm not sugarcoating anything, I'm just looking at the situation rationally as if I wasn't invested
profile image
@Olli68 well. New debt can make sense from an investment perspective. If your internal investment yields more than the interest.

And slowing growth is totally normal, isn't it? It's in the nature of every company. In pharma in particular, the target group is simply limited
profile image
Huh ? The Q3 figures are already there ?!
Join the conversation